Vincent's Hospital Manhattan, locally referred to as "St. Vincent's". St. Vincent's was founded in 1849 and was a major teaching hospital in the Greenwich Village neighborhood of Manhattan, New York City. It closed on April 30, 2010, under circumstances that triggered an investigation by the Manhattan District Attorney. Demolition began at the end of 2012 and was completed in early 2013. Other hospital buildings are being converted into luxury condos and a new luxury building, Greenwich Lane, has replaced the St. Vincent's building. St. St. St. St.
The Sterile Processing and Distribution (SPD) department is responsible for cleaning, disinfecting, inspecting, and assembling surgical instruments between surgeries. Manual inspection and preparation of instrument trays is a time-consuming, error-prone task, often prone to contamination and instrument breakage. In this work, we present a fully automated robotic system that sorts and structurally packs surgical instruments into sterile trays, focusing on automation of the SPD assembly stage. A custom dataset comprising 31 surgical instruments and 6,975 annotated images was collected to train a hybrid perception pipeline using YOLO12 for detection and a cascaded ResNet-based model for fine-grained classification. The system integrates a calibrated vision module, a 6-DOF Staubli TX2-60L robotic arm with a custom dual electromagnetic gripper, and a rule-based packing algorithm that reduces instrument collisions during transport. The packing framework uses 3D printed dividers and holders to physically isolate instruments, reducing collision and friction during transport. Experimental evaluations show high perception accuracy and statistically significant reduction in tool-to-tool collisions compared to human-assembled trays. This work serves as the scalable first step toward automating SPD workflows, improving safety, and consistency of surgical preparation while reducing SPD processing times.
Objective.Bioimpedance spectroscopy (BIS) has emerged as a promising technique for screening cervical intraepithelial neoplasia (CIN) since the electrical properties vary with the pathological status of cervical tissues. In this study, we aimed to evaluate the ability of CIN screening using multiple features extracted from BIS measurements collected with a multi-electrode BIS probe.Approach.This study enrolled 161 patients with gynecological diseases, including 44 with and 117 without cervical dysplasia. Upon the histological diagnosis, the samples were classified as normal, CIN I, and CIN II with p16 positive (p16(+))/CIN III. Complex impedance spectra ofin vitrocervical conization tissues were measured using the BIS probe. A Cole-Cole plot was generated from each patient's data measured on the conized cervix, and various features were extracted. Receiver operating characteristic (ROC) curves were generated, and the area under each ROC curve (AUC) was calculated.Main results.As a result, fifteen features from Cole-Cole plots differed significantly (p<0.01) between normal cervices and CIN. The AUCs based on multiple features, as determined by multivariable logistic regression, were 0.93 for normal cervix vs CIN I, 0.99 for normal cervix vs CIN II p16(+)/CIN III, and 0.94 for normal cervix vs CIN. These AUCs were improved by 14.8%, 7.6%, and 8.0%, respectively, compared with the results based on features extracted from only the real part of the impedance spectra.Significance.In conclusion, CIN can be accurately diagnosed using multiple features extracted from the impedance spectrum ofin vitrocervical samples. Particularly, this method was highly accurate in classifying CIN II p16(+)/CIN III, which has a higher risk of progression to cancer.
Abstract Background: Metastatic uveal melanoma (mUM) has a very poor prognosis with a historical survival rate of <10% at 5 yrs. Tebentafusp, a first in class ImmTAC bispecific (gp100 x CD3), is approved for adult HLA-A*02:01+ patients with unresectable or mUM based on a phase 3 study demonstrating improved overall survival (OS) compared to investigator’s choice (IC) (HR 0.51; IMCgp100-202; NCT03070392). This benefit was maintained at the 3-yr follow-up (HR 0.68), with a 3-yr OS rate of 27% for tebentafusp and 18% for IC. Molecular response assessed by ctDNA reduction was a better indicator of OS benefit than traditional RECISTv1.1 measurements. Here we report updated analyses of OS after a minimum follow-up of 5 yrs. Methods: In this randomized, open-label, Phase 3 trial, first line HLA-A*02:01+ mUM patients were randomized 2:1 to receive tebentafusp or IC of single-agent pembrolizumab, ipilimumab or dacarbazine, stratified by lactate dehydrogenase. Primary endpoint was OS. ctDNA reduction was an exploratory endpoint. OS was estimated using Kaplan-Meier methods and treatment effects compared using Cox proportional hazards model. A Cox model, adjusted for baseline and time-varying covariates at progression, compared post-progression survival in tebentafusp patients with versus without treatment beyond radiographic progression (TBP). Results: 378 patients were randomized to tebentafusp (252) or IC (126; 82% pembrolizumab). With extended follow-up, the OS continued to favor tebentafusp, with a stratified hazard ratio of 0.67 (95% CI, 0.54-0.85). The 5-year OS rate for tebentafusp was 16% (95% CI, 11-21) vs 8% (95% CI, 4-14) for IC. The OS benefit was evident even in patients with known poor prognostic factors, including those with large tumors ≥ 10 cm. OS benefit was also seen in patients who did not have radiographic response including those with best response of progressive disease (PD) or those with a best change of tumor growth (>20%). Notably, in the tebentafusp arm, TBP was associated with better OS compared to no TBP, even after adjusting for covariates (HR 0.61; 95% CI, 0.44-0.83). In tebentafusp-treated patients, longer OS was associated with undetectable ctDNA at baseline or ctDNA reductions ≥50% by week 9. Among 21 ctDNA-evaluable patients who survived ≥ 5 years, 15 had undetectable baseline ctDNA and the remaining 6 had ctDNA clearance. Deep reductions in ctDNA were seen in patients regardless of baseline tumor burden and across all RECIST categories. Conclusions: Tebentafusp demonstrates durable, long-term OS benefit in first line HLA-A*02:01+ patients, which at 5 years is the longest OS follow-up in a randomized trial in mUM. OS benefit is evident in those with poor prognostic factors and remains independent of radiographic response, with ctDNA levels proving to be a better indicator of activity. This is the first report of long-term OS benefit in a solid tumor treated with an ImmTAC therapy. Citation Format: Paul Nathan, Sophie Piperno-Neumann, Jessica C. Hassel, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Reinhard Dummer, John M. Kirkwood, Joseph J. Sacco, Alexander N. Shoushtari, Josep M. Piulats, April KS Salama, Marlana Orloff, Anthony M. Joshua, Sebastian Ochsenreither, Lauris Gastaud, Brendan Curti, Lev Demidov, Mohammed Milhem, Bartosz Chmielowski, Kari Kendra, Paolo Antonio Ascierto, Eric H. Bernicker, Richard D. Carvajal, Omid Hamid, Laura Collins, Sarah Lockwood, Jaymin M. Patel, Jean-Francois Baurain, Piotr Rutkowski. Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr CT029.
BACKGROUND:Tebentafusp demonstrated an overall survival benefit compared with investigator's choice in a phase 3 trial in HLA-A∗02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) and is now the first-line standard of care for this population. In this study, we report the final 5-year analysis of overall survival. PATIENTS AND METHODS:In this international, open-label, phase 3 trial, previously untreated HLA-A∗02:01-positive patients with mUM were randomized 2:1 to receive tebentafusp or investigator's choice of pembrolizumab, ipilimumab, or dacarbazine (control group), stratified by lactate dehydrogenase. The primary endpoint was overall survival; circulating tumor DNA (ctDNA) reduction was an exploratory endpoint. RESULTS:After a minimum of 5 years of follow-up, median overall survival was 21.6 months in the tebentafusp group and 16.9 months in the control group (stratified hazard ratio 0.67, 95% confidence interval 0.54-0.85). Overall survival at 5 years was 16% versus 8%, respectively. Tebentafusp improved survival even in poor-prognosis groups, such as patients with baseline tumors ≥10 cm or those whose best RECISTv1.1 response was progressive disease, including cases where target tumor growth exceeded 20%. After adjusting for covariates, a post hoc analysis showed that patients who were treated with tebentafusp beyond radiographic progression had longer overall survival than those who discontinued treatment. In the tebentafusp group, longer overall survival was associated with undetectable ctDNA at baseline or ctDNA reductions ≥50% by week 9. Deep ctDNA reductions occurred regardless of baseline tumor burden or radiographic response. CONCLUSIONS:In the longest survival follow-up of a randomized trial in mUM, tebentafusp continues to provide long-term survival benefit in previously untreated HLA-A∗02:01-positive patients. CLINICALTRIALS: GOV IDENTIFIER:NCT03070392.
BACKGROUND In sub-Saharan Africa in Tanzania, with an incidence of 1.4/100,000 cases. A lot of cancer cases in Tanzania are not diagnosed until later because there aren't many healthcare institutions offering cancer-related care and treatment. Cancer that manifests in its late stages not only reduces survival chances but also places a heavy load on the healthcare system. a lower-middle-income nation, has numerous barriers to receiving treatment for children's malignancies. The research aims to study the clinical presentation and types of childhood cancer at the Muhimbili National Hospital. METHODS A hospital-based cross-sectional survey and convenience sample technique were used to assess the presentation and association factors of childhood cancer. Descriptive statistics and statistical analysis to assess associations among variables were performed through chi2 and one-way ANOVA. A p-value of <0.05 was considered significant. RESULTS 141 patients were assessed; the most common types of cancer were Blastoma and Leukaemia between 1 and 5 years. The Sukuma tribe had the highest percentage of patients. Most of the patients came from Dar es Salaam. The majority of patients presented with masses and abdominal distention. There was a statistically significant difference between family history and the type of cancer, between the stage of disease and response to treatment, and between the ages across types of cancer. There is no statistical difference or association between the type of cancer and the history of chronic illness or exposure. CONCLUSION Childhood cancer has high mortality and morbidity in Tanzania. Most of the patients die before 5 years old, and patients come to the hospital with a late-stage disease with serious symptoms. Other patients didn’t complete treatment, which may be due to financial problems or a low level of education among carers. ### Competing Interest Statement The authors have declared that no competing interests exist. ### Funding Statement The author(s) received no specific funding for this work. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The approval from the hospital administration has been granted by the medical director's office at Muhimbili National Hospital (MNH). As well as the approval of the research department. The Ethics Committee of the Muhimbili National Hospital at Der es salaam Tanzania approved the study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All relevant data are within the manuscript and its Supporting Information files
